|
CN202139694U
(zh)
|
2011-06-17 |
2012-02-08 |
清华大学 |
一种复式钢管混凝土柱与钢梁连接节点
|
|
WO2013155223A1
(en)
|
2012-04-10 |
2013-10-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
WO2014160200A1
(en)
|
2013-03-13 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Ras inhibitors and uses thereof
|
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
|
TW201524952A
(zh)
|
2013-03-15 |
2015-07-01 |
Araxes Pharma Llc |
Ｋｒａｓ ｇ１２ｃ之共價抑制劑
|
|
MX380928B
(es)
|
2013-10-10 |
2025-03-12 |
Araxes Pharma Llc |
Inhibidores de kras g12c.
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
WO2016203406A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
JP6869947B2
(ja)
|
2015-07-22 |
2021-05-12 |
アラクセス ファーマ エルエルシー |
置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
KR102932353B1
(ko)
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
|
ES2863873T3
(es)
|
2016-05-18 |
2021-10-11 |
Mirati Therapeutics Inc |
Inhibidores de KRAS G12C
|
|
KR102218333B1
(ko)
|
2016-06-07 |
2021-02-22 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
|
PT3468972T
(pt)
|
2016-06-14 |
2020-08-21 |
Novartis Ag |
Compostos e composições para inibir a atividade da shp2
|
|
IL311645B2
(en)
|
2016-07-12 |
2025-11-01 |
Revolution Medicines Inc |
2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
|
|
EP3515916B1
(en)
|
2016-09-22 |
2023-06-07 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
TW202500565A
(zh)
|
2016-10-24 |
2025-01-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
|
CR20190338A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso
|
|
CN110446709B
(zh)
|
2017-01-23 |
2023-09-12 |
锐新医药公司 |
作为变构shp2抑制剂的二环化合物
|
|
CA3051054A1
(en)
|
2017-01-23 |
2018-07-26 |
Revolution Medicines, Inc. |
Pyridine compounds as allosteric shp2 inhibitors
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US20200385364A1
(en)
|
2017-01-26 |
2020-12-10 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
SG11201908820VA
(en)
|
2017-03-23 |
2019-10-30 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
|
WO2018206539A1
(en)
|
2017-05-11 |
2018-11-15 |
Astrazeneca Ab |
Heteroaryl compounds that inhibit g12c mutant ras proteins
|
|
UA127968C2
(uk)
|
2017-05-22 |
2024-02-28 |
Емджен Інк. |
Інгібітори g12c kras і способи їх застосування
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
US11591336B2
(en)
|
2017-05-26 |
2023-02-28 |
D. E. Shaw Research, Llc |
Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
|
|
TWI852912B
(zh)
|
2017-09-07 |
2024-08-21 |
美商銳新醫藥公司 |
Shp2抑制劑組合物以及治療癌症的方法
|
|
US10640504B2
(en)
|
2017-09-08 |
2020-05-05 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
JP7447002B2
(ja)
|
2017-09-11 |
2024-03-11 |
クルーゾン・ファーマシューティカルズ・インコーポレイテッド |
ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
|
|
EP3687997A1
(en)
|
2017-09-29 |
2020-08-05 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
BR112020007058A2
(pt)
|
2017-10-12 |
2020-10-06 |
Revolution Medicines, Inc. |
compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
|
|
CA3082579A1
(en)
|
2017-11-15 |
2019-05-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
US10597405B2
(en)
|
2017-12-08 |
2020-03-24 |
Astrazeneca Ab |
Chemical compounds
|
|
BR112020009757A2
(pt)
|
2017-12-15 |
2020-11-03 |
Revolution Medicines, Inc. |
compostos policíclicos como inibidores alostéricos de shp2
|
|
SG10202102462SA
(en)
|
2018-01-19 |
2021-04-29 |
Medshine Discovery Inc |
Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
US11498930B2
(en)
|
2018-02-13 |
2022-11-15 |
Blueray Therapeutics (Shanghai) Co., Ltd |
Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
|
|
WO2019165073A1
(en)
|
2018-02-21 |
2019-08-29 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
RU2020133727A
(ru)
|
2018-03-21 |
2022-04-21 |
Сучжоу Пухе Биофарма Ко., Лтд. |
Ингибиторы shp2 и их применение
|
|
US12138263B2
(en)
|
2018-03-21 |
2024-11-12 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
|
|
CN117263942A
(zh)
|
2018-03-21 |
2023-12-22 |
传达治疗有限公司 |
Shp2磷酸酶抑制剂及其使用方法
|
|
KR20200143417A
(ko)
|
2018-04-10 |
2020-12-23 |
레볼루션 메디슨즈, 인크. |
Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법
|
|
KR102611661B1
(ko)
|
2018-05-02 |
2023-12-08 |
나비레 파르마, 인코퍼레이티드 |
Ptpn11의 치환된 헤테로사이클릭 억제제
|
|
EP3788053B1
(en)
|
2018-05-04 |
2024-07-10 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
MA53395A
(fr)
|
2018-07-24 |
2021-06-02 |
Otsuka Pharma Co Ltd |
Composés hétérobicycliques pour inhiber l'activité de shp2
|
|
US11518770B2
(en)
|
2018-08-06 |
2022-12-06 |
Purdue Research Foundation |
Sesquiterpenoid analogs
|
|
PL3833670T3
(pl)
|
2018-08-10 |
2024-08-19 |
Navire Pharma, Inc. |
Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka
|
|
CN112839935A
(zh)
|
2018-09-26 |
2021-05-25 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
|
JP2022508651A
(ja)
|
2018-10-08 |
2022-01-19 |
レヴォリューション・メディスンズ，インコーポレイテッド |
癌を処置するためのｓｈｐ２阻害剤組成物および方法
|
|
MA53921A
(fr)
|
2018-10-17 |
2022-01-26 |
Array Biopharma Inc |
Inhibiteurs de protéine tyrosine phosphatase
|
|
CN117143079A
(zh)
|
2018-11-06 |
2023-12-01 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物及其应用
|
|
US12281118B2
(en)
|
2018-11-07 |
2025-04-22 |
Shanghai Ringene Biopharma Co., Ltd. |
Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use
|
|
JP7377679B2
(ja)
*
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
WO2020108590A1
(zh)
|
2018-11-30 |
2020-06-04 |
上海拓界生物医药科技有限公司 |
嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
|
|
US12377101B2
(en)
*
|
2018-12-05 |
2025-08-05 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CN113316574B
(zh)
|
2019-01-31 |
2024-01-30 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
|
WO2020156243A1
(zh)
|
2019-01-31 |
2020-08-06 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
|
CN111647000B
(zh)
|
2019-03-04 |
2021-10-12 |
勤浩医药（苏州）有限公司 |
吡嗪类衍生物及其在抑制shp2中的应用
|
|
US11033547B2
(en)
|
2019-03-07 |
2021-06-15 |
Merck Patent Gmbh |
Carboxamide-pyrimidine derivatives as SHP2 antagonists
|
|
CN113646049B
(zh)
|
2019-04-08 |
2024-08-13 |
默克专利有限公司 |
作为shp2拮抗剂的嘧啶酮衍生物
|
|
CA3142430A1
(en)
|
2019-06-07 |
2020-12-10 |
Revolution Medicines, Inc. |
Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
|
|
CN117209471A
(zh)
|
2019-06-14 |
2023-12-12 |
北京盛诺基医药科技股份有限公司 |
一种shp2磷酸酶变构抑制剂
|
|
US20220380385A1
(en)
|
2019-06-28 |
2022-12-01 |
Tuojie Biotech(Shanghai) Co., Ltd. |
Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
|
|
CN112300160A
(zh)
|
2019-08-01 |
2021-02-02 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物、其制备及应用
|
|
EP3772513A1
(en)
|
2019-08-09 |
2021-02-10 |
C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening |
Shp2 inhibitors
|
|
GB201911928D0
(en)
|
2019-08-20 |
2019-10-02 |
Otsuka Pharma Co Ltd |
Pharmaceutical compounds
|
|
WO2021043077A1
(zh)
|
2019-09-06 |
2021-03-11 |
四川科伦博泰生物医药股份有限公司 |
一种取代吡嗪化合物、其制备方法和用途
|
|
CN114502165A
(zh)
|
2019-09-23 |
2022-05-13 |
苏州浦合医药科技有限公司 |
Shp2抑制剂及其用途
|
|
EP4034539A1
(en)
|
2019-09-24 |
2022-08-03 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of making and using the same
|
|
CN112724145A
(zh)
|
2019-10-14 |
2021-04-30 |
杭州雷索药业有限公司 |
用于抑制shp2活性的吡嗪衍生物
|
|
WO2021088945A1
(zh)
|
2019-11-08 |
2021-05-14 |
南京圣和药业股份有限公司 |
作为shp2抑制剂的化合物及其应用
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
US20240082218A1
(en)
*
|
2020-12-22 |
2024-03-14 |
Novartis Ag |
Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
|
|
WO2022133731A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Novartis Ag |
Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
|